Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients.
Okeke Constance O, Quigley Harry A, Jampel Henry D, Ying Gui-shuang, Plyler Ryan J, Jiang Yuzhen, Friedman David S
AI Summary
A multifaceted intervention significantly improved adherence to once-daily glaucoma drops in non-adherent patients, highlighting that targeted support can boost medication use.
Abstract
Purpose
To investigate the impact of an intervention program to improve adherence with topical, once daily therapy for glaucoma.
Design
Randomized controlled clinical trial.
Participants
Sixty-six patients with glaucoma being treated with a prostaglandin analog in 1 or both eyes at the Scheie Eye Institute or Wilmer Eye Institute between November 2006 and June 2007.
Methods
In an observational study, participants who took 75% or fewer doses (as measured using the travoprost Dosing Aid [DA]) during an initial 3-month period were randomized into 2 groups. The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices. The control group was told to take drops as prescribed and received no additional intervention.
Main outcome measures
Change in drop use adherence as determined by the DA device.
Results
In the 3-month observation period before randomization, intervention group patients had used a mean of 54+/-17% of scheduled doses, and this increased to 73+/-22% during the following 3-month period (P<0.001, n = 35). The control mean adherence rate of 46+/-23% at baseline was statistically unchanged during the follow-up observation period (51+/-30%, P = 0.16, n = 31). In a multivariate analysis, intervention, baseline compliance rate of <50%, and white ethnicity were predictors of improved adherence during the 3 months of intervention. The intraocular pressure (IOP) of the intervention and control groups did not change between months 3 and 6 after intervention (P = 0.96, 0.34, respectively), and there was no correlation of IOP change with adherence rate change between both groups (Pearson correlation r = 0.06, P = 0.51).
Conclusions
A multifaceted intervention significantly increased adherence with glaucoma medications. Those with improved adherence were in the intervention group, had very low adherence rates at baseline, and were white. IOP did not correlate with adherence. Further research is needed to determine which components of this intervention were most effective.
MeSH Terms
Shields Classification
Related Articles5
Antihypertensive Medication Timing and Cardiovascular Events and Death: The BedMed Randomized Clinical Trial.
Randomized Controlled TrialReal-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration.
Retrospective StudyPreservatives and ocular surface disease: A review.
ReviewThe Carbon Footprint of Glaucoma Care With Drops or Laser First.
Observational StudyClinical Outcomes of Therapeutic Interventions for Autoimmune Retinopathy: A Meta-analysis and Systematic Review.
Meta-AnalysisIs this article assigned to the wrong chapter(s)? Let us know.